Full Press Release Details
Therapeutics Announces Executive Management Promotions
Nicholson named Senior Vice President & Chief Operating Officer of Nektar; Gil M. Labrucherie named Senior Vice President
& Chief Financial Officer of Nektar
Francisco, CA, June 2, 2016 - Nektar Therapeutics (NASDAQ: NKTR) announced today that John Nicholson has been named
Senior Vice President & Chief Operating Officer and Gil M. Labrucherie has been named Senior Vice President & Chief Financial
Officer of Nektar. Mr. Nicholson has served as the Chief Financial Officer of Nektar since 2007. Mr. Labrucherie has served as
Senior Vice President, General Counsel and Secretary of Nektar since 2007.
am very pleased to announce these two well-deserved promotions on Nektar's Executive Committee," said Howard W. Robin,
President & CEO of Nektar. "Both John and Gil have played an integral role in Nektar's growth and development
over the past eight years. John has a strong record of performance and financial leadership within Nektar and he brings over thirty
years of experience in the pharmaceutical industry to the newly-created role of Senior Vice President & Chief Operating Officer
has demonstrated exceptional business acumen and strong leadership skills during his tenure at Nektar and I am delighted that
he will now bring his insight and expertise to the position of Senior Vice President & Chief Financial Officer," Robin
Nicholson, in the newly-created role of Senior Vice President & Chief Operating Officer, will be responsible for leading global
business and corporate development, marketing, quality assurance, and Nektar project management for the company's partnered
programs and wholly-owned pipeline candidates.
the tenure of his career, Mr. Nicholson has held key senior leadership roles in the areas of operations, marketing, sales and
corporate strategy. Prior to joining Nektar, Mr. Nicholson, served in a number of leadership roles at Bayer Schering Pharma AG,
including Vice President, Corporate Development and Treasurer of Schering Berlin Inc., President of Schering Berlin Insurance
Company, President of Bayer Pharma Chemicals Inc., and President of Schering Berlin Capital Corporation.
his new role as Senior Vice President & Chief Financial Officer, Mr. Labrucherie will be responsible for leading the company's
finance and accounting teams, information technologies and services, logistics, and will continue to provide oversight for all
legal functions, including intellectual property. Mr. Labrucherie has held several senior
leadership positions with increasing responsibility at Nektar since 2005. Prior to joining Nektar, from October 2000 to
September 2005, Mr. Labrucherie was Vice President of Corporate Development at E2open, Inc., where he was responsible for global
corporate alliances and merger and acquisition activity. Prior to E2open, he was the Senior Director of Corporate Development
at AltaVista Company, an Internet search company, where he was
responsible for merger and acquisition transactions. Mr. Labrucherie began his career as an associate in the corporate practice
of the law firm of Wilson Sonsini Goodrich & Rosati and Graham & James (DLA Piper Rudnick). Mr. Labrucherie received his
J.D. from University of California Boalt Hall School of Law, where he was a member of the California Law Review and Order of the
Coif, and received his B.A. from the University of California, Davis.
Therapeutics has a robust R&D pipeline and portfolio of approved partnered medicines in oncology, pain, immunology and other
therapeutic areas. In the area of oncology, Nektar is developing NKTR-214, an immuno-stimulatory CD122-biased agonist, that is
in Phase 1/2 clinical development for patients with solid tumors. ONZEALD (etirinotecan pegol), a long-acting topoisomerase
I inhibitor, is being developed for patients with advanced breast cancer and brain metastases and is partnered with Daiichi Sankyo
in Europe. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for MOVANTIK (naloxegol),
the first FDA-approved once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment
of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. The product is also approved in the European
Union as MOVENTIG (naloxegol) and is indicated for adult patients with OIC who have had an inadequate response to laxatives.
The AstraZeneca agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of MOVANTIK and
an opioid. NKTR-181, a wholly owned mu-opioid analgesic molecule for chronic pain conditions, is in Phase 3 development. In hemophilia,
Nektar has a collaboration agreement with Baxalta for ADYNOVATE [Antihemophilic Factor (Recombinant)], a longer-acting
PEGylated Factor VIII therapeutic approved in the U.S. and Japan for patients over 12 with hemophilia A. In anti-infectives, the
company has two collaborations with Bayer Healthcare, Cipro Inhale in Phase 3 for non-cystic fibrosis bronchiectasis and Amikacin
Inhale in Phase 3 for patients with Gram-negative pneumonia.
technology has enabled nine approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies,
including AstraZeneca's MOVANTIK , Baxalta's ADYNOVATE , UCB's Cimzia for Crohn's disease and rheumatoid arthritis,
Roche's PEGASYS for hepatitis C and Amgen's Neulasta for neutropenia.
is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further
information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.
is a trademark and MOVENTIG is a registered trademark of the AstraZeneca group of companies. ADYNOVATE is a trademark